Vergoeding 2015-2019 voor ATC-subgroep J05AB : Nucleosiden en nucleotiden (excl. reverse-transcr-remmers)
- Raming voor de totale Zvw-populatie
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| J05AB01 Aciclovir (Zovirax ®) | 402.760 | 386.510 | 370.910 | 321.030 | 264.200 |
| J05AB04 Nucleosiden en nucleotiden (excl. reverse-transcr-remmers) | 406.110 | 55.110 | 5.384 | . | . |
| J05AB06 Ganciclovir (Cymevene ®) | 1.639 | 2.348 | 44 | . | 165 |
| J05AB09 Famciclovir | 1.506.500 | 1.469.800 | 1.462.600 | 1.321.300 | 1.262.700 |
| J05AB11 Valaciclovir (Zelitrex ®) | 1.367.500 | 1.327.100 | 1.185.800 | 1.640.300 | 1.970.200 |
| J05AB14 Valganciclovir (Valcyte ®) | 5.202.500 | 4.896.100 | 2.792.200 | 1.106.800 | 1.062.300 |
| Totaal | 8.887.009 | 8.136.968 | 5.816.938 | 4.389.430 | 4.559.565 |